Drug Information |
Recognizing Psychiatric Disorders in Adolescents and Young Adults: A Guide for Prescribers of Accutane (isotretinoin)
Psychiatric Risk Management–AccutaneWARNINGSPsychiatric Disorders: Accutane may cause depression, psychosis and, rarely, suicidal ideation, suicide attempts and suicide. Discontinuation of Accutane therapy may be insufficient; further evaluation may be necessary. No mechanism of action has been established for these events (see ADVERSE REACTIONS: Psychiatric). Pseudotumor Cerebri: Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines. Concomitant treatment with tetracyclines should therefore be avoided. Early signs and symptoms of pseudotumor cerebri include papilledema, headache, nausea and vomiting, and visual disturbances. Patients with these symptoms should be screened for papilledema and, if present, they should be told to discontinue Accutane immediately and be referred to a neurologist for further diagnosis and care (see ADVERSE REACTIONS: Neurological) ADVERSE REACTIONSNeurological: pseudotumor cerebri (see WARNINGS: Pseudotumor Cerebri), dizziness, drowsiness, headache, insomnia, lethargy, malaise, nervousness, paresthesias, seizures, stroke, syncope, weakness Psychiatric: suicidal ideation, suicide attempts, suicide, depression, psychosis (see WARNINGS: Psychiatric Disorders), emotional instability Of the patients reporting depression, some reported that the depression subsided with discontinuation of therapy and recurred with reinstitution of therapy. Reporting Adverse Events Specific information about adverse events that occur during Accutane therapy may be reported either to Roche Medical Services at 1-800-526-6367 or to the Food and Drug Administration MedWatch Program at 1-800-FDA-1088. Accutane (isotretinoin)Accutane is a retinoid related to vitamin A. Patients should be advised against taking vitamin supplements containing vitamin A to avoid additive toxic effects. Recognizing Psychiatric Disorders in Adolescents and Young AdultsIntroduction Mental health problems are underdiagnosed and undertreated.1 Dermatologists and other Accutane prescribers often see patients who are otherwise healthy, and they may be among the only professionals who have opportunities to evaluate patients' mental health. Healthcare providers who recognize the signs and symptoms of psychiatric illness and respond appropriately can improve, and perhaps even save, their patients’ lives. Accutane may cause depression, and more rarely other psychiatric disorders. In some cases, the psychiatric illness is severe and there have been suicide attempts and suicides. Although causality has not been established for these reports, awareness of signs and symptoms may save your patient’s life. This brochure provides an overview of depression. The goal of this brochure is to help you identify when a psychiatric referral may be appropriate for your patients. You and your staff may feel uncomfortable evaluating your patients’ mental health status. It is often difficult to distinguish clinical depression from other responses. It may also be difficult to decide whether erratic behavior may warrant psychiatric evaluation, especially if that behavior seems to be age-appropriate in a teenager. However, as with any specialized problem, you may identify patients who seem to need more than dermatologic care, and you may need to refer them to a specialist. Knowing when to make a referral for a patient who may be at psychiatric risk can make a major difference in the patient’s life—in extreme cases, it can mean the difference between life and death. Depression Depression and suicidal tendencies are two important psychiatric conditions that may be observed in dermatology and family practice settings. This brochure provides an overview of depression, because depression is the most commonly reported psychiatric adverse event in patients taking Accutane, and is also a well-established risk factor for suicidal behavior. Depression is characterized by symptoms including intense, persistent sadness; anxiety; loss of pleasure from usual activities; and loss of energy.2 These feelings can be normal responses to a negative life event, but clinical depression is either not triggered by such an event or is disproportional to the trigger.3 Depression can be episodic. According to the National Comorbidity Survey, 17% of Americans will experience depression at some point during their lives and 5% are depressed in any given month.4, 5 Several epidemiological studies reported that up to 8.3% of adolescents in the United States suffer from depression.6 Depression can take several forms; three of the most common are dysthymia, major depression, and bipolar disorder.2 These three disorders are characterized by various combinations of the symptoms listed in Table 1. Not every patient exhibits all depressive symptoms. Some patients, especially adolescents, may display irritability instead of sadness. TABLE 1. Symptoms of Depression2
Dysthymia has characteristics similar to those of major depression but is not as disabling. People with dysthymia often function adequately but not at previous wellness levels, and are at risk for episodes of major depression. In major depression, a combination of symptoms prevents the patient from working, studying and/or engaging in normal activities. In bipolar disorder, the patient alternates between periods of depression and episodes of mania (euphoric feelings).2 Symptoms of Mania (National Institute of Mental Health (NIMH))
Suicide Suicide accounts for more than 30,000 American deaths each year. It is the third leading cause of death (after accidents and homicide) among people aged 15 to 24, which makes it responsible for more deaths in this age group than any physical illness.7, 8 Healthcare providers often miss the warning signs because patients may hide suicidal intent very successfully. In fact, 60% of people who commit suicide had seen a physician within 1 month of their deaths.9 Suicidal tendencies rarely arise spontaneously; 93% of people who commit suicide suffer from depression, schizophrenia and/or substance abuse.10 Up to 60% of adolescents and young adults think about suicide at some point,7 but fortunately these thoughts usually pass. Few people who have suicidal thoughts make the attempt, and most attempts at suicide are unsuccessful.8 An analysis of completed suicides showed the following common characteristics:11
Women are twice as likely as men to attempt suicide, but men are four times more likely to be successful. Women usually use means from which they may be rescued, such as a drug overdose,12 whereas men tend to use firearms or automobiles. Firearms are used in 58% of all completed suicides.8 Despite a patient’s attempt to hide suicidal thoughts, he or she may send deliberate warning signals, some of which can be explicit.2 Every mention or discussion of "killing myself" should be treated with utmost seriousness. Causes of Depression The causes of depression are often multi-factorial and may include:
Evaluating and Referring Patients for Psychiatric Disturbance Although only 5% of the population is depressed at any given time, the incidence has been found to be closer to 15% to 20% in primary care settings.11 Given that 1 in 5 patients who come to your office may have some degree of depression, a few questions can identify patients who may be at risk. Asking the Right Questions While taking a history, the prescriber should suspect the likelihood of depression if the patient has symptoms such as:6
In children and young adolescents, other signs to look for include:
The prescriber should also discuss with the patient:
Studies indicate that acne is associated with symptoms such as social embarrassment, low self esteem, and anxiety, but an association of acne with frank depressive disorders has not been established nor has treatment of acne by itself been shown to ameliorate frank depressive disorders.16, 17, 18 Talking About Depression Although it can be awkward to explain to a patient that he or she may have signs of depression (or any mental illness), the awkwardness can be minimized by reminding the patient that:
Suicide Screening Psychiatric specialists have identified several factors for suicide risk. These include:12
It is important to note that depression itself is a major risk factor for suicidal behavior. Thus, special attention is needed when prescribing drugs that may cause depression. An association with Accutane should be considered in patients with signs and symptoms of depression, even in the presence of other life stressors. Discontinuation of Accutane may be insufficient intervention and formal psychiatric evaluation should be conducted. It is also important to note that signs and symptoms of depression are not included in all reported cases of suicidal behavior. It is not known if this means the signs were masked by the patient, unrecognized by observers, or if the suicidal tendency arose impulsively. It is important that patients taking Accutane be made aware of this so that they might recognize any such signs and symptoms. Patients (and parents, if the patient is a minor) should be instructed to stop Accutane and seek immediate medical help. Talking with patients about suicide does not encourage or remind them that suicide is an option.11 Knowing When to Refer You should refer the patient to a psychiatric specialist for further evaluation if any of the following apply:
Summary Prescribers who are alert to the warning signs of psychiatric disorders can guide patients to receive the help they need. Observing patients for signs of depression and suicidal ideation, and referring appropriate patients to a psychiatric specialist, need not be complicated. The benefits to patients can be immense, even life-saving. References 1. Brody DS, Dietrich AJ, DeGruy F III, Kroenke K. The depression in primary care tool kit. Int J Psychiatry Med. 2000;30:99-110. 2. National Institute of Mental
Health. Depression. Available at: 3. Berkow R, Beers MH, Fletcher AJ, Bogin RM, eds. The Merck Manual of Medical Information: Home Edition. Sec. 7, Ch 84. Depression and Mania. http://www.merck.com /pubs/mmanual_home/Sec7/84.htm. Accessed 5/3/01. 4. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:8-19. 5. Blazer DG, Kessler RC, McGonagle KA, Swartz MS. The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey. Am J Psychiatry. 1994:151:979-986. 6. National Institute of Mental Health. Depression in Children and Adolescents. A Fact Sheet for Physicians. Bethesda, MD: US Dept of Health and Human Services; September 2000. NIMH Publication no. 00-4744. Available at: http://www.nimh.nih.gov/publicat/depchildresfact.cfm. 7. Zaph R II. Adolescent
suicide attempts. Available at: 8. National Institute of Mental Health. Suicide facts. Available at: http://www.nimh.nih.gov/research/suifact.htm. Accessed 4/24/01. 9. Jacobs DG, Deutsch NL. Recognizing suicide potential in women. Women’s Health in Primary Care. 1998;1(7):560-571. 10. Goodwin FK, Runck BL. Suicide intervention. In: Jacobs D, ed. Suicide and Clinical Practice. Washington, DC: American Psychiatric Press; 1992:1-21. 11. National Depression Screening Day® primary care outreach. Diagnostic Aid for Depression in the Primary Care Setting. 12. Screening for suicide risk. [Guide to Clinical Preventive Services, 2nd ed. Mental Disorders and Substance Abuse.] Available at: http://cpmcnet.columbia.edu/texts/gcps/gcps0060.html. Accessed 4/24/01. 13. Wells VE, Deykin EY, Klerman GL. Risk factors for depression in adolescence. Psychiatr Dev. 1985;3:83-108. 14. Monroe SM, Rhode P, Seeley JR, Lewinsohn PM. Life events and depression in adolescence: relationship loss as a prospective risk factor for first onset of major depressive disorder. J Abnorm Psychol. 1999;108:606-614. 15. Medications (American Psychiatric Association DIAGNOSTIC AND STATISTICAL MANUAL – TEXT REVISION (DSM-IV-TR, 2000) 16. Niemeier V, Kupfer J, Demmelbauer-Ebner M, Stangier U, Effendy I, Gieler U.Coping with acne vulgaris. Evaluation of the chronic skin disorder questionnaire in patients with acne. Dermatology. 1998;196:108-115. 17. Kellet SC, Gawkrodger DJ. The psychological and emotional impact of acne and the effect of treatment with isotretinoin. Brit J Dermatol. 1999;140:273-282. 18. Rubinow DR, Peck GL, Squillace KM, Gantt GG. Reduced anxiety and depression in cystic acne patients after successful treatment with oral isotretinoin. J Am Acad Dermatol. 1987;17:25-32. Back to Top Back to Accutane page FDA/Center for Drug Evaluation and Research |